DIAGENS

What DIAGENS does

Hangzhou Diagens Biotechnology Co., Ltd. (DIAGENS) is a Chinese medical-imaging AI company that develops, manufactures, and commercializes in-vitro diagnostic devices and laboratory automation systems centered on chromosome karyotype analysis. Its proprietary iMedImage® foundation model powers the AI AutoVision® Chromosome Karyotype Assisted Diagnosis System — the world's first product of its kind to receive a Class III Medical Device Registration Certificate from China's NMPA — alongside a hardware and consumables portfolio that includes AutoVision®, MetaSight® automatic cell microscopic image scanners, and the KayoFlow® line of cytogenetics laboratory automation (cell harvester, slide preparation and staining systems, integrated workflow).

The platform is commercialized through a B2B enterprise model with three revenue streams: (1) hardware and reagent sales of AI-powered medical devices to hospital cytogenetics laboratories, fertility clinics, and reproductive-health providers in China, where Diagens holds 30.6% market share in the chromosome karyotype analysis market per Frost & Sullivan; (2) technology licensing of the iMedImage® foundation model to other healthcare-technology players, which grew 331.7% year-over-year to RMB 84.3 million in 2025; and (3) the iMed MaaS Medical Imaging AI Platform, a model-as-a-service offering with on-premise storage, computation, training and inference infrastructure for hospitals. The company employs 51–100 people, is headquartered in Hangzhou, and listed on the Hong Kong Stock Exchange in March 2026, positioning it as the world's first publicly listed company offering AI tools built on a medical imaging foundation model.

Name

DIAGENS

Legal name

Hangzhou Diagens Biotechnology Co., Ltd.

Website

https://diagens.com

Company type

Private

Founded year

2016

Operating status

Operating

Headcount range

51–100 employees

Short description

DIAGENS is a Hangzhou-based medical-imaging AI company that sells AI-powered chromosome karyotype analysis systems, cytogenetics lab automation, and an iMedImage® foundation model platform to hospitals, fertility clinics, and clinical labs in China.

Ownership category

akta.pro rank

Product category

Medical Imaging AI Diagnostics

NAICS

Navigational, Measuring, Electromedical, and Control Instruments Manufacturing (3345), In-Vitro Diagnostic Substance Manufacturing (325413)

SIC

Surgical & Medical Instruments & Apparatus (3841), In Vitro & In Vivo Diagnostic Substances (2835)

akta.pro primary industry

SaMD – Imaging & Signal Analysis (AI/ML) (HLACANAG)

akta.pro secondary industries

AI Orchestration & Imaging Analytics Platforms (Model Management/Triage) (HLACALAG), Radiology AI, CAD & Advanced Visualization Software (HLAHABAJ), Digital & AI-Enabled Diagnostics (algorithmic interpretation, decision support tied to assays) (HLAAALAO), Medical Imaging AI (HDAAAEAH)

Keywords

• AI medical imaging
• Chromosome karyotype analysis
• Cytogenetics laboratory automation
• Medical imaging foundation model
• AI diagnostic devices

Headquarters

HQ city

Hangzhou

HQ country

China

HQ region

Asia

Offices1 record

Markets served

GTM type

B2B

Offering type

Software

Cost components

Technology or R&D, Personnel, Marketing or Sales, Operations, Supply Chain, Infrastructure

Revenue model

1. AI Medical Device Product Sales: Sale of AI-powered medical devices including AI AutoVision® Chromosome Karyotype Assisted Diagnosis System, AutoVision® Chromosome Karyotype Analysis System, MetaSight® scanning systems, and KayoFlow® laboratory automation equipment to hospitals and clinical laboratories.
2. Technology Licensing Revenue: Licensing of the iMedImage® foundation model and AI analysis capabilities to other healthcare technology companies and institutions. Technology licensing revenue surged 331.7% year-over-year to RMB 84.3 million in 2025.
3. iMed MaaS (Medical Imaging AI Platform): Model-as-a-Service platform providing integrated storage, computation, training and inference solutions for medical imaging AI deployment.

Pricing tiers

Go-to-market motion2 records

Distribution channels2 records

Marketing channels3 records

Core offering

DIAGENS develops and sells AI-powered medical imaging devices and software for chromosome karyotype analysis, cytogenetics laboratory automation, and reproductive genetics diagnostics. Its product portfolio includes the AI AutoVision® and AutoVision® chromosome analysis systems, MetaSight® cell microscopic image scanners, the KayoFlow® lab automation suite (cell harvester, slide preparation, staining, integrated workflow), and cytogenetics reagents and consumables. The company also licenses its proprietary iMedImage® foundation model and offers the iMed MaaS medical imaging AI platform with localized storage, computation, training, and inference infrastructure for healthcare institutions.

Product overview

DIAGENS (Hangzhou Diagens Biotechnology Co., Ltd.) offers a platform-plus-modules architecture centered on AI-powered medical imaging solutions. The core technology is the proprietary iMedImage® Foundation Model, which powers flagship products including AI AutoVision® (world's first Class III NMPA-approved chromosome karyotype AI analysis system) and AutoVision® Chromosome Karyotype Analysis System. These are complemented by laboratory automation products under the KayoFlow® brand (cell harvester, slide preparation/staining system, and integrated workflow) and MetaSight® automatic cell microscopic image scanning. The company also provides the iMed MaaS Medical Imaging AI Platform for deployment, along with localized infrastructure solutions. Solution offerings span AI-Driven Genetics Health (reproductive health), AI-Driven Radiological Health, and AI-Driven Hematology Solutions, with technology licensing emerging as a significant revenue stream.

Differentiator

Problem solved

Functional benefit

Brands

• iMedImage®: Foundation model technology platform for medical imaging AI analysis
• AI AutoVision®
• AutoVision®
• MetaSight®
• KayoFlow®
• iMed MaaS

Products and services

• AI AutoVision® Chromosome Karyotype Assisted Diagnosis System AI-powered chromosome karyotype analysis system that received the world's first Class III Medical Device Registration Certificate from China's NMPA. Achieves 100% sensitivity and specificity for numerical abnormality detection and reduces analysis time from 34 minutes to 11 minutes per case.
• AutoVision® Chromosome Karyotype Analysis System Chromosome karyotype analysis system for cytogenetics laboratories, providing automated microscopic image analysis for genetic testing.
• MetaSight® Automatic Cell Microscopic Image Scanning System Automated cell microscopic image scanning system for high-throughput cytogenetic analysis and screening.
• KayoFlow® Cytogenetics Automatic Cell Harvester Automated cell harvester for cytogenetics laboratory workflows, enabling standardized cell sample preparation.
• KayoFlow® Integrated Slide Preparation and Staining System Integrated system for automated slide preparation and staining in cytogenetics testing.
• KayoFlow® Workflow Complete workflow solution integrating KayoFlow® cell harvester and slide preparation systems for end-to-end cytogenetics laboratory automation.
• Cytogenetics Laboratory Reagents and Consumables Specialized reagents and consumables for cytogenetics laboratory testing and chromosome analysis procedures.
• iMed MaaS Medical Imaging AI Platform Medical Imaging AI Platform (MaaS) providing integrated storage, computation, training and inference solutions for deploying AI models in healthcare settings.
• iMedImage® Foundation Model Proprietary medical imaging foundation model that powers AI AutoVision® and other AI diagnostic products. Validated through NMPA Class III approval process and licensed to healthcare technology companies.
• Integrated Storage, Computation, Training and Inference Localized Solution On-premise AI infrastructure solution enabling hospitals and laboratories to deploy, train, and run AI models with localized data processing.
• AI-Driven Genetics Health Solutions AI-powered solutions for reproductive genetics and reproductive health testing services, including chromosome analysis for prenatal and fertility diagnostics.
• AI-Driven Radiological Health Solutions AI-powered radiological health solutions applying computer vision and deep learning to medical imaging analysis.
• AI-Driven Hematology Solutions AI-powered solutions for hematology and oncology applications, supporting diagnostic workflows in blood disorder analysis.
• iMedImage® Model Service Portfolio Model service portfolio based on iMedImage® foundation model, offering AI model licensing and customization services for medical imaging applications.

Quantifiable outcome

• Reduces chromosome analysis time from 34.42 minutes to 11.19 minutes (68% reduction)
• +4 more outcomes

Named customers2 records

Segments4 records

Ideal customer profiles3 records

Technology focussed Yes

API detail

Has API

No

API docs

API detail

Core technology

AI maturity

App detail

AI capability5 records

Feature4 records

Partnerships

One partnership is on record.

• The Chinese University of Hong KongcoreStrategic or Co-development Partner · 15 May 2026The Chinese University of Hong Kong signed a memorandum of understanding with Hangzhou Diagens Biotechnology to develop medical AI imaging for maternal and child healthcare in China's Greater Bay Area.

Scale indicators10 records

Recent moves7 records

Expansion highlights6 records

Broad incumbents

• Infervision (推想科技): Beijing-based AI medical imaging company providing AI solutions for radiology, pathology, and clinical workflows across Chinese hospitals. Comparable as a Chinese AI medical imaging platform company serving hospitals with imaging AI, though focused on radiology/CT rather than cytogenetics.
• Novogene: Beijing-based genomics services and diagnostics company with strong sequencing capabilities and clinical genetics offerings. Comparable as a Chinese genomics/diagnostics company serving research institutions and clinical customers, though primarily a sequencing services provider.
• BGI Genomics: Largest Chinese genomics and diagnostics company offering NIPT, reproductive health, oncology, and clinical sequencing services. Comparable as a Chinese reproductive health/genetic testing incumbent that competes for hospital cytogenetics and genetic testing budgets, though much larger and broader in scope.
• United Imaging Intelligence: AI subsidiary of United Imaging Healthcare, providing AI-driven imaging analysis solutions across CT, MR, and pathology. Comparable as a Chinese AI medical imaging platform serving hospitals, leveraging a broader equipment-installed base.

Direct peers

• Annoroad Genomics: Beijing-based genomics and reproductive health testing company serving Chinese clinical markets with cytogenetics, NIPT, and genetic testing services. Comparable as a Chinese reproductive genetics diagnostics company with similar hospital customer base.
• Berry Genomics: Beijing-based genetic testing and genomics company providing NIPT, reproductive health diagnostics, and cytogenetics services in China. Directly comparable as a Chinese reproductive genetics diagnostics company serving hospitals and clinical labs with chromosome-related testing.
• Genetron Holdings: Beijing-based precision oncology and genetic testing company serving Chinese hospitals with NGS-based diagnostics. Comparable as a Chinese molecular diagnostics company pursuing hospital channel sales in reproductive health and oncology genetics.

Emerging players

• Yitu Technology (依图科技): Shanghai-based AI company with healthcare imaging AI offerings among broader AI applications. Comparable as a Chinese AI medical imaging player with hospital channels, though facing its own commercialization and regulatory challenges.
• Shukun Technology (数坤科技): Beijing-based AI medical imaging company focused on cardiovascular and radiological AI solutions for Chinese hospitals. Comparable as a Chinese medical imaging AI company pursuing hospital deployment and regulatory approvals in adjacent imaging verticals.

Regional players

• Burning Rock Biotech: Guangzhou-based oncology-focused NGS diagnostics company serving Chinese hospitals. Comparable as a Chinese molecular diagnostics company leveraging AI/computational approaches in clinical genomics, though primarily focused on oncology rather than cytogenetics.

Market position

Strengths5 records

Weaknesses5 records

Competitive moat4 records

Key risks6 records

Key highlights6 records

Customer concentration

Compliance2 records

Revenue estimate

Valuation estimate

Number of profiles

Funding overview

Funding rounds4 records

Investors9 records

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

M&A

Investments

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Frequently asked questions about DIAGENS